Table 1 Tumour response and survival rate in patients treated with Transarterial Embolization (TAE)

Loewe et al. 2003[7]

23 carcinoids

75 TAE

4 (18%) CR, 12 (55%) PR, 6 (27%) PD (22 pts evaluable)

69 months

Gupta et al. 2003[18]

69 carcinoids

Carcinoids:

Carcinoids: 46 (67%) PR, 6 (8.5%) MR, 11 (16%) SD, 6 (8.5%) PD

18 months

54 PNENs

42 TAE/27 TACE

PNEN: 19 (35%) PR, 1 (2%) MR, 32 (59%) SD, 2 (4%) PD

PNENs:

32 TAE/22 TACE

Carrasco et al. 1986[32]

25 carcinoids

25 TAE

20 (87%) CR, 1 (5%) PD

11 months

(23 evaluable)

Strosberg et al. 2006[36]

59 carcinoids

161 TAE

23 pts evaluable: 11 (48%) PR, 12 (52%) SD

36 months

20 PNENs

5 unspecified NENs

Hanssen et al. 1989[39]

19 carcinoids (7 evaluable)

7 TAE

7 (100%) PR

12 months

Wangberg et al. 1996[40]

64 carcinoids

40 TAE

---

60 months

Eriksson et al. 1998[41]

29 carcinoids

55 TAE

Carcinoids: 18 (62%) CR, 9 (31%) SD, 2 (7%) PD

80 months (carcinoids)

12 PNENs

PNEN: 6 (67%) CR, 1 (11%) SD, 2 (22%) PD

20 months (PNEN)

Brown et al. 1999[42]

21 carcinoids

63 TAE

---

60 months

14 PNENs

Chamberlain et al. 2000[43]

41 carcinoids

59 TAE

33 pts evaluable: 19 (58%) SD

NR

44 PNENs

Ruutiainen et al. 2007[44]

67 unspecified NENs

23 TAE/44 TACE

(100%) CR

36 months

(219 procedures)

(35%) CR

Ho et al. 2007[45]

31 carcinoids

7 TAE/86 TACE

33 pts evaluable:

48 months

15 PNEN

Carcinoids: 5 (23%) PR, 5 (23%) MR, 7 (31%) SD, 5 (23%) PD*

PNEN: 2 (18%) PR, 3 (27%) MR, 5 (46%) SD, 1 (9%) PD*

Kamat et al. 2008[46]

60 unspecified NENs

33 TAE/27 TACE

12 (25%) PR, 6 (12%) MR, 22 (46%) SD, 8 (17%) PD*

9.3 months

(123 procedures)

48 pts evaluable

Pitt et al. 2008[47]

100 unspecified NENs

106 TAE/123 TACE

---

32.4 months

Sward et al. 2009[48]

107 carcinoids

213 TAE

---

56 months

Fiore et al. 2014[50]

12 PNENs

38 TAE/37 TACE

17 pts evaluable:

60 months

16 NENs ileum

12 (70%) CR, 5 (30%) PR

2 NENs colon